“Double carbapenem” and oral fosfomycin for the treatment of complicated urinary tract infections caused by blaNDM‐harboring Enterobacteriaceae in kidney transplantation

Infections with carbapenemase‐producing carbapenem‐resistant Enterobacteriaceae represent an emergent problem worldwide. Treatment of infections caused by New Delhi metallo‐beta‐lactamase (NDM)‐harboring Enterobacteriaceae is particularly challenging as it frequently involves the use of nephrotoxic agents, which is problematic in kidney transplant recipients and non‐renal transplant patients with marginal kidney function. We present two cases of urinary tract infections caused by NDM‐harboring Enterobacteriaceae successfully treated with a combination of “double carbapenem” and oral fosfomycin.

[1]  R. Humphries,et al.  Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae? , 2017, Antimicrobial Agents and Chemotherapy.

[2]  R. Bonomo,et al.  Successful treatment of a disseminated infection with extensively drug‐resistant Klebsiella pneumoniae in a liver transplant recipient with a fosfomycin‐based multidrug regimen , 2016, Transplant infectious disease : an official journal of the Transplantation Society.

[3]  L. Pączek,et al.  Successful Treatment of Urinary Tract Infection in Kidney Transplant Recipients Caused by Multiresistant Klebsiella pneumoniae Producing New Delhi Metallo-Beta-Lactamase (NDM-1) With Strains Genotyping. , 2016, Transplantation proceedings.

[4]  K. Kaye,et al.  Infections Caused by Resistant Gram‐Negative Bacteria: Epidemiology and Management , 2015, Pharmacotherapy.

[5]  R. Cantón,et al.  Successful Treatment of Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae Bacteremia , 2015, Antimicrobial Agents and Chemotherapy.

[6]  J. Camargo,et al.  Intravenous Fosfomycin Treatment for Carbapenem-Resistant Klebsiella pneumoniae in the United States , 2015, The Annals of pharmacotherapy.

[7]  T. Walsh,et al.  The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  A. Dessen,et al.  Resistance to antibiotics targeted to the bacterial cell wall , 2014, Protein science : a publication of the Protein Society.

[9]  O. Cars,et al.  Evaluation of Double- and Triple-Antibiotic Combinations for VIM- and NDM-Producing Klebsiella pneumoniae by In Vitro Time-Kill Experiments , 2014, Antimicrobial Agents and Chemotherapy.

[10]  G. Keating.  Fosfomycin Trometamol: A Review of Its Use as a Single-Dose Oral Treatment for Patients with Acute Lower Urinary Tract Infections and Pregnant Women with Asymptomatic Bacteriuria , 2013, Drugs.

[11]  D. van Duin,et al.  Multidrug‐Resistant Gram‐Negative Bacteria Infections in Solid Organ Transplantation , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  A. Michalopoulos,et al.  The revival of fosfomycin. , 2011, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[13]  M. Falagas,et al.  Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. , 2009, International journal of antimicrobial agents.

[14]  N. Shrestha,et al.  Fosfomycin: A Review , 2001 .

[15]  P. Nordmann,et al.  In vitro evaluation of dual carbapenem combinations against carbapenemase-producing Enterobacteriaceae. , 2016, The Journal of antimicrobial chemotherapy.

[16]  D. Paterson,et al.  Carbapenemase-Producing Enterobacteriaceae , 2015, Seminars in Respiratory and Critical Care Medicine.

[17]  V. Seija,et al.  Sepsis caused by New Delhi metallo-β-lactamase (blaNDM-1) and qnrD-producing Morganella morganii, treated successfully with fosfomycin and meropenem: case report and literature review. , 2015, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[18]  J. Samet,et al.  Food and Drug Administration , 2007, BMJ : British Medical Journal.